ClinicalTrials.gg
CompletedNCT04298658HIPPIUpdated Nov 12, 2026Results posted

The Impact of Insomnia on Pain in HIV

An observational study in HIV and Insomnia, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Alabama at Birmingham · Observational

How we know

Updated Nov 12, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
171
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Enrollment
16th of 49
171 · median 68
Started
2020
with 48 others
Observational
49 of 907
7 open now
Registered
541st of 907
by date

Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 16th largest by enrollment of the 49 observational ones that give a count, is one of 49 that started in 2020, is one of 49 observational ones, and was the 541st registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

144 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

The overall objective of this application is to investigate the impact of insomnia on pain, physical functioning, and inflammation in people living with HIV. The two aims of this study to determine 1) whether insomnia promotes increased sensitivity and inflammatory reactivity to pain stimuli, and 2) if weekly fluctuations in insomnia burden drive changes in inflammation, pain severity, and physical functioning in people living with HIV. This research could help confirm insomnia as a therapeutic target for the suppression of pain and inflammation in people living with HIV.

Read the detailed description

This study was conducted during the height of the COVID19 pandemic. Recruitment and retention were significantly and negatively affected. The longitudinal time-course was reduced from 8 consecutive weeks of observation down to 3 weeks. We were only able to recruit 171 of an anticipated 200 participants.

Week 1: 171 total participants Week 2: 136 total participants Week 3: 35 participants (insomnia only)

Week 1 Resting Blood Pressure and Body Mass Index will be assessed. Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test. Study staff will administer the Structured Interview for Sleep Disorders and administer the Rapid Estimation of Adult Literacy Measure-Short Form (REALM-SF) to determine health literacy. The night of Experimental Session 1 participant will be using a Resmed ApneaLink Air device (Resmed, San Diego, CA), to identify apnea and hypopnea and calculate an apnea hypopnea index.

Between Week 1 and Week 2 Sleep assessment: Sleep data will be collected by participants in their own homes using objective and subjective measures of their sleep. Participant instructions for how to collect and record their own sleep data will be provided at the end of study session 1. Participant will be provided with a watch-like device to wear on wrist for 7 consecutive days and nights. This watch measures physical activity and sleep.

Week 2 Resting Blood Pressure and temperature will be assessed. A sample of urine will be taken to test for illicit substances that might affect the study's results. Experimental session 2 will take place in the Center for Clinical and Translational Science (CCTS) Clinical Research Unit (CRU). A clinical Research Unit (CRU) nurse will place an intravenous (IV) cannula (small plastic tube) in the arm using a needle to draw blood at the beginning of the session and then an additional four times across the study for a total of five blood draws. Participants will complete multiple questionnaires to measure health, and experience with insomnia, pain, mood and emotions, experiences with stigma and discrimination, and how participant thinks and feels about things. All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 3-4 hours. Blood will be processed and stored and then used to measure inflammation.

Week 3 Only participants with insomnia (with and without HIV) will complete a battery of ecologically valid movement tasks that include: 1) Performance Battery (SPPB) which includes sitting in a chair, transitioning to a standing position, balancing tests and gait speed, and the Timed Up and Go test (TUG). A clinical Research Unit (CRU) nurse will draw a quick sample of approximately 20 milliliters from the participants arm using a butterfly needle so that CRU nurse can collect blood during the beginning of each visit.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

120 individuals with HIV (60 with insomnia \& 60 without insomnia) as well as a group of 120 individuals without HIV as Controls (60 with insomnia \& 60 without insomnia), for a total sample size of 240 individuals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

with Insomnia

  • Confirmed HIV diagnosis
  • currently a patient in the University of Alabama (UAB) 1917 HIV Clinic.
  • must be currently receiving stable antiretroviral therapy (ART).
  • Meets the -5 (DSM-5) diagnostic criteria for insomnia including sleep difficulty.

HIV Without Insomnia

  • Confirmed HIV diagnosis
  • currently a patient in the University of Alabama (UAB) 1917 HIV Clinic.
  • must be currently receiving stable antiretroviral therapy (ART).
  • Does not meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for insomnia including sleep difficulty.

Non HIV with Insomnia

  • Confirmed Non HIV diagnosis and currently not a patient in the UAB 1917 HIV Clinic.
  • Meets DSM-5 diagnostic criteria for insomnia including sleep difficulty.

Non HIV Without Insomnia

  • Confirmed Non HIV diagnosis and currently not a patient in the UAB 1917 HIV Clinic.
  • Does not meets DSM-5 diagnostic criteria for insomnia including sleep difficulty.

Exclusion criteria

Exclusion Criteria:

  • concurrent medical conditions that could confound
  • interpretation of sleep
  • pain
  • inflammatory issues or coexisting diseases
  • Systemic rheumatic disease/condition
  • uncontrolled hypertension (i.e., BP > 150/95)
  • circulatory disorders (e.g., Reynaud's disease)
  • history of heart disease or cardiac events
  • history of cancer
  • asthma AND use of an inhaler
  • history of seizures
  • history of stroke or other neurological disorder
  • pregnancy
  • core body temperature > 100 degrees Fahrenheit as this could indicate acute infection with fever; (k)
  • unwilling to provide blood for this study
  • non-English speaking
  • recent injury or surgical procedure within past 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
171 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • HIV and Insomnia

    Participants will test positive for HIV and Insomnia.

    Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: Cluster of Differentiation 4 (CD4) and Viral load

  • HIV Without Insomnia

    Participants will test positive for HIV and test negative for Insomnia.

    Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: Cluster of Differentiation 4 (CD4) and Viral load

  • Non HIV with Insomnia

    Participants will test negative for HIV and test positive for Insomnia.

    Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: OraQuick Advance Rapid HIV 1/2 Swab test

  • Non HIV Without Insomnia

    Participants will test negative for HIV and test negative for Insomnia.

    Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: OraQuick Advance Rapid HIV 1/2 Swab test

Interventions

  • Diagnostic testStructured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised

    Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)

    Also known as: Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R)

  • Diagnostic testResmed ApneaLink Air device (Resmed, San Diego, CA).

    Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).

    Also known as: Home Sleep Test

  • OtherQuantitative Sensory testing (QST)

    All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.

  • Diagnostic testOraQuick Advance Rapid HIV 1/2 Swab test

    Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.

    Also known as: OraQuick

  • Diagnostic testCluster of Differentiation 4 (CD4) and Viral load

    Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.

06

What researchers measure

Primary outcomes

  1. Pro-Inflammatory Markers

    TNF-a, IL-6, IL-12, IL-18, C-reactive protein, sCD14/163, D-dimer and IFN-gamma assays will be performed on the blood to identify levels of pro-inflammatory markers.

    Time frame: Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples

  2. Anti-Inflammatory Markers

    IFN-a, TGF-B, IL4, IL-10 and IL-13 assays will be performed on the blood to identify levels of anti-inflammatory markers.

    Time frame: Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples

  3. Oxidative Stress Markers

    Mitochondrial DNA damage, Damage associated molecular patterns (DAMPS) and Cortisol assays will be performed on the blood to identify levels of oxidative stress markers.

    Time frame: Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples

  4. Pain Threshold

    Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful"

    Time frame: pain threshold assessed at Week 2; data is average of three assessments

  5. Pain Tolerance

    Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation.

    Time frame: pain tolerance assessed at Week 2; data is average of three assessments

  6. Punctate Stimuli

    Mechanical temporal summation was assessed using a nylon Von Frey Filament (Stoelting Co., 6.65 g), which is calibrated to bend at 300 g of pressure. The filament was applied to the back of the non-dominant hand for approximately 1 second until the monofilament bent slightly. Participants were instructed to rate their pain level using the 0-100 Numeric Rating Scale (higher numbers represent greater pain). The filament was then applied to the skin for a series of 10 consecutive applications. Participants were instructed to rate the highest level of pain they experienced during the trial. This process was repeated for two trials (2 single trials, 2 series of 10). For each trial, a difference score was calculated between the series of 10 applications and the single presentation, which represented mechanical TS. The difference score was averaged across the two trials.

    Time frame: mechanical temporal summation of pain assessed at Week 2; data is average of two test trials

  7. Temporal Summation of Pain

    Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. A series of 5 heat pulses will be repeated every two seconds starting at a baseline temperature of 40 and participants will be asked to rate how painful each peak of the pulse feels to them using a pain rating of 0-100 numeric rating scale. Pain intensity was assessed using a 0-100 numeric rating scale, where 0 indicates no pain and 100 indicates the worst pain imaginable. Participants rated their pain intensity, with higher scores indicating greater pain severity. Temperatures included 44, 46, and 48 degrees in Celsius.

    Time frame: heat temporal summation of pain assessed at Week 2; data presented is the average of 5 heat pulses completed at 44, 46, and 48 degrees in Celsius.

  8. Conditioned Pain Modulation

    A cold-water bath (conditioning stimulus) was set to 10°C prior to the visit. Participants placed their non-dominant hand in the water bath up to their wrist for a maximum of 60 seconds. Immediately after withdrawal of the hand from the cold water, pressure was then applied to the dominant forearm or trapezius muscle using an algometer (testing stimulus). Participants were instructed to press a button when they first felt pain, resulting in termination of the stimuli. This procedure was repeated for a total of 4 trials (2 on each body site) and body site order was randomized (i.e., Forearm, Trapezius, Forearm, Trapezius, Forearm). An average pressure pain threshold score (kiloPascals - kPa of pressure) was generated across the two trials at each site after water immersion. Conditioned pain modulation was calculated as the difference score between baseline pressure pain threshold (kPa) and the average pressure pain threshold after water immersion at each body site

    Time frame: Week 2

  9. Actigraph Sleep Measurement

    A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light.

    Time frame: seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average

  10. Weekly Sleep Diaries

    A sleep diary including daily questions will be filled out every day for seven days including questions about a participants nightly sleep experiences.

    Time frame: Baseline up to 8 weeks

  11. Weekly Caffeine Diaries

    A caffeine dairy including different types of caffeine generally available for the participants to record their daily caffeine consumption of for seven days.

    Time frame: Baseline up to 8 weeks

  12. Actigraph Sleep Measurement

    A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light. The primary actigraphic sleep outcome presented here is sleep efficiency. Sleep efficiency will be assessed using wrist-worn actigraphy and calculated as the percentage of time spent asleep relative to the total time spent in bed during the designated sleep period. Sleep efficiency is derived by dividing total sleep time by time in bed and multiplying by 100. The mean scores presented here are percentages. Higher percentages indicate greater sleep efficiency.

    Time frame: seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average

Secondary outcomes

  1. Short Physical Performance Battery

    The Short Physical Performance Battery consists of 3 individual sub-tests - standing balance (participants are asked to stand in 3 easy stances for 10 seconds), 4-meter gait speed (participants are asked to walk a steady pace in a straight line for 4-meters) and 5-repetition sit-to-stand (participants are asked to stand up and sit back down in a stable chair up to 5 times). All 3 are simple and quick to perform in the outpatient setting and require only limited equipment. The total short physical performance battery score ranges from 0-12, with higher scores indicating better physical performance.

    Time frame: Completed at Week 3 by people with insomnia only

Other outcomes

  1. Timed Up and Go (TUG) Task

    The Timed Up and Go test (TUG) is a commonly used screening tool to assist clinicians to identify patients at risk of falling. Participants are asked to start in a sitting position in a chair, stand up and walk approximately 3 meters before turning to return to the chair at a steady, straight pace. The outcome will be measured with a stopwatch, then rating difficulty 0-100 (0 no difficulty and 100 being the most difficult imaginable) and pain 0-100 (0 no pain and 100 being the most pain imaginable).

    Time frame: Completed at Week 3 by people with insomnia only

  2. Munich Chrono Type Questionnaires (MCTQ)

    The Munich Chronotype Questionnaire (MCTQ) estimates chronotype primarily from the midpoint of sleep on free days, called MSF (mid-sleep on free days), with MSFsc (sleep-corrected MSF) generally preferred because it adjusts for accumulated weekday sleep debt. The outcome reported in this trial is expressed in minutes - "mid-sleep time on free days, sleep-corrected (minutes). Higher values represent a later/evening chronotype, whereas lower values represent an earlier/morning chronotype.

    Time frame: Baseline

  3. Insomnia Severity Index (ISI)

    The Insomnia severity index is a 7 item measure that has each participant subjectively measure their insomnia severity. Each is rated from 0 (none/not at all) to 4 (very severe/very much). The responses are summed to produce a total score that ranges from 0 to 28; higher scores suggest great subjective insomnia severity.

    Time frame: ISI completed Week 1

  4. Demographics (DEMO)

    This questionnaire better helps the investigators understand how each participant's financial, racial, social, etc. background. It ranges from general questions such as age and birthday, to socioeconomic questions such as work status and financial stability.

    Time frame: Baseline

  5. Center for Epidemiological Studies - Depression (CESD)

    The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report measure of depressive symptoms experienced during the past week, with each item scored 0-3 for a total of 0-60. Commonly used cutoffs are \<16 = no significant depressive symptomatology, 16-26 = mild/moderate symptoms, and ≥27 = severe symptoms, although the CES-D is a screening measure rather than a diagnostic instrument. Higher scores indicate greater depressive symptom burden.

    Time frame: CESD completed Week 1

  6. RU Sated

    Sleep is a key aspect in an individual's everyday life. This questionnaire measures overall sleep quality in six different categories---Regularity, Sleep quality, alertness, timing, efficiency, and duration. This helps investigators understand a person's sleep efficacy.

    Time frame: RU Sated completed Week 1

  7. Physical Health Questionnaire (PHQ-15)

    The PHQ-15 (Patient Health Questionnaire-15) is a 15-item self-report measure of somatic symptom burden, with each symptom scored 0 (not bothered), 1 (bothered a little), or 2 (bothered a lot), producing a total score of 0-30. Commonly used severity categories are 0-4 = minimal, 5-9 = low, 10-14 = medium, and 15-30 = high somatic symptom severity.

    Time frame: Baseline

  8. Difficulties in Emotion Regulation Scale (DERS)

    The Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report measure assessing difficulties with emotion regulation across six domains, with items typically rated 1 (almost never) to 5 (almost always), yielding a total score of 36-180. Higher scores indicate greater emotion-regulation difficulties, and there are no universally accepted clinical cutoff scores; scores are generally interpreted relative to normative samples or as continuous measures of emotion-regulation difficulty.

    Time frame: Baseline

  9. Dysfunctional Beliefs and Attitudes About Sleep (DBAAS)

    The Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) assesses maladaptive beliefs and expectations about sleep; the commonly used DBAS-16 contains 16 items rated on a 0-10 scale, producing a mean score from 0-10. Higher scores indicate stronger dysfunctional sleep beliefs.

    Time frame: Week 1

  10. Pain Interference and Intensity (PI-I)

    This questionnaire seeks to understand how pain has an influence/impacts an individual's everyday life and activities, sleep, and mood in general. Pain intensity and interference in everyday life was assessed using a 0-5 numeric rating scale, where 0 indicates no pain and 5 indicates the worst pain imaginable. Participants rated their pain intensity and interference, with higher scores indicating greater pain severity.

    Time frame: Week 2

  11. Sorge 24 Hour Food Record

    Dietary intake will be assessed using Sorge 24-hour Food Records. These records will be analyzed with the Nutrition Data System for Research (NDSR), a computer-based dietary assessment software developed by the Nutrition Coordinating Center at the University of Minnesota. Trained interviewers document all foods, beverages, and, when applicable, dietary supplements consumed during the preceding 24 hours. Information regarding food type, portion size, ingredients, preparation methods, and consumption occasions will be collected to improve the completeness and accuracy of dietary reporting. The reported dietary intake will be entered into NDSR and the resulting data may include total energy intake, macronutrients, micronutrients, and other dietary components. NDSR access is proprietary and requires a subscription. We did not have the funds to access NDSR and thus we do not have resulting data to present. The numbers below represent completed 24 hour food records for each group.

    Time frame: Food record completed once during Week 2

  12. Sorge Dietary Habits

    This questionnaire asks about a person's general diet and intake.

    Time frame: Sorge dietary habits completed once at Week 2

  13. Drug Abuse Screening Test (DAST10)

    The DAST-10 (Drug Abuse Screening Test-10) is a 10-item self-report screening measure of drug-related problems, with each yes/no item scored 0 or 1, producing a total score of 0-10. Common interpretation is 0 = no problems, 1-2 = low level, 3-5 = moderate, 6-8 = substantial, and 9-10 = severe drug-related problems; it is a screening tool rather than a diagnostic measure.

    Time frame: Week 2

  14. State Trait Anxiety Inventory

    The State-Trait Anxiety Inventory-Trait (STAI-T) is a 20-item self-report measure of relatively stable, enduring anxiety proneness, with each item rated 1-4, producing a total score of 20-80. Higher scores indicate greater trait anxiety, but there are no universally accepted clinical severity cutoffs; scores are generally interpreted relative to normative populations, with higher scores reflecting greater anxiety tendency.

    Time frame: Week 2

  15. Penn State Cigarette Dependence Index - Cigarettes

    The Penn State Cigarette Dependence Index (PSCDI) is a brief self-report measure of cigarette dependence, assessing factors such as smoking frequency, time to first cigarette, and difficulty refraining from smoking. The commonly used 9-item version produces a score of 0-9, with higher scores indicating greater nicotine dependence; there are no universally accepted clinical severity cutoffs, so scores are typically interpreted continuously or using study-specific thresholds.

    Time frame: Week 2

  16. Penn State Cigarette Dependence Index - Ecigarettes

    The Penn State Electronic Cigarette Dependence Index (Penn State ECigarette Dependence Index; PS-ECDI) is a brief self-report measure of e-cigarette/vaping dependence, assessing features such as frequency of use, time to first use, and difficulty refraining. The 10-item version is scored from 0-20, with higher scores indicating greater e-cigarette dependence; commonly used categories are 0-3 = no dependence, 4-8 = low, 9-12 = moderate, 13-16 = high, and 17-20 = very high dependence.

    Time frame: Week 2

  17. Alcohol Use Disorders Identification Test - C (AUDIT)

    The AUDIT-C (Alcohol Use Disorders Identification Test-Consumption) is a 3-item screening measure of alcohol consumption, with each item scored 0-4, producing a total score of 0-12. Higher scores indicate greater alcohol consumption and likelihood of hazardous drinking.

    Time frame: Week 2

  18. Alcohol Smoking and Substance Involvement Screening Test (ASSIST)

    This questionnaire detects and measures substance abuse, alcohol, and smoking as well as related problems. It aims to detect the risky behavior related to each.

    Time frame: Baseline up to 1 week

  19. Anger PROMIS

    The 22-item PROMIS Anger scale is a self-report measure of anger and irritability, with each item typically rated from 1 (never) to 5 (always), yielding a raw score of 22-110. Higher raw scores indicate greater anger, but raw scores are not usually interpreted with fixed clinical severity cutoffs.

    Time frame: Week 2

  20. Perceived Stress Scale (PSS)

    The Perceived Stress Scale (PSS) is a 10-item self-report measure assessing how unpredictable, uncontrollable, and overwhelming respondents have found their lives during the past month. Each item is scored 0-4, producing a total raw score of 0-40; higher scores indicate greater perceived stress, but there are no universally accepted clinical severity cutoffs, so scores are generally interpreted continuously.

    Time frame: Week 2

  21. Pain Catastrophizing Scale (PCS)

    The Pain Catastrophizing Scale (PCS) is a 13-item self-report measure assessing three aspects of pain catastrophizing: rumination, magnification, and helplessness. Each item is scored 0-4, producing a total raw score of 0-52; higher scores indicate greater pain catastrophizing, with ≥30 commonly used as a clinically relevant level of catastrophizing.

    Time frame: Week 2

  22. HIV Stigma Mechanisms

    the HIV Stigma Mechanisms Scale (HIV-SMS) assesses three distinct dimensions of HIV-related stigma: enacted (promulgated) stigma, internalized stigma, and anticipated stigma. The original 24-item instrument uses separate five-point response scales for each dimension. Scoring and interpretation * Enacted stigma (9 items): Participants report how frequently they have experienced stigmatizing treatment because of their HIV status, using a five-point scale from 1 (never) to 5 (very often). * Internalized stigma (6 items): Participants rate their agreement with statements reflecting negative feelings or beliefs about themselves because of their HIV status, using a five-point scale from 1 (strongly disagree) to 5 (strongly agree). * Anticipated stigma (9 items): Participants rate how likely they believe others are to treat them in stigmatizing ways because of their HIV status, using a five-point scale from 1 (very unlikely) to 5 (very likely).

    Time frame: Week 2

  23. Heightened Vigilance Scale (HVS)

    The Heightened Vigilance Scale is a 6-item self-report measure assessing the extent to which individuals feel they must remain alert and cautious because of the possibility of experiencing unfair treatment or discrimination. Each item is typically rated on a 1-6 scale, producing a total score of 6-36, with higher scores indicating greater perceived vigilance.

    Time frame: Week 2

  24. Experience of Discrimination (EOD)

    The 9-item Experiences of Discrimination (EOD) measure assesses lifetime experiences of discrimination across nine settings, including school, employment, housing, health care, and public settings. Each item is scored according to whether the participant reports experiencing discrimination in that setting. For a situation-based total score, responses are coded as 0 (no) or 1 (yes) and summed across the nine items, yielding a total score ranging from 0 to 9. Higher scores indicate experiences of discrimination across a greater number of settings and therefore represent a worse outcome.

    Time frame: Week 2

  25. Adverse Childhood Experiences (ACE)

    The Adverse Childhood Experiences (ACE) Questionnaire is a 10-item retrospective self-report measure assessing exposure to potentially traumatic or stressful experiences before age 18, including abuse, neglect, and household dysfunction. Each experience is typically scored 0 (no) or 1 (yes), producing a total ACE score of 0-10, with higher scores indicating exposure to a greater number of adverse childhood experiences

    Time frame: Week 2

  26. Lee Fatigue Scale (LFS)

    The Lee Fatigue Scale (LFS) is an 18-item self-report measure assessing fatigue severity and energy level, with items rated on a 0-10 scale. Scores are typically averaged across items to produce a 0-10 overall fatigue score, with higher scores indicating greater fatigue

    Time frame: Week 3

07

Results

Posted Nov 12, 2026
Limitations and caveats
This study was conducted during the height of the COVID19 pandemic. Recruitment and retention were significantly and negatively affected. The longitudinal time-course was reduced from 8 consecutive weeks of observation down to 3 weeks. We were only able to recruit 171 of an anticipated 200 participants. Week 1: 171 total participants Week 2: 136 total participants Week 3: 35 participants (insomnia only)

Participant flow

This study was conducted during the height of the COVID19 pandemic. Recruitment and retention were significantly and negatively affected. The longitudinal time-course was reduced from 8 consecutive weeks of observation down to 3 weeks. We were only able to recruit 171 of an anticipated 200 participants. Week 1: 171 total participants Week 2: 136 total participants Week 3: 35 participants (insomnia only)

Participant flow — Overall Study
MilestoneHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Started53214354
Week 153214354
Week 246371439
Week 3140210
Completed53214354
Not completed0000

Outcome measures

PrimaryPro-Inflammatory Markers

TNF-a, IL-6, IL-12, IL-18, C-reactive protein, sCD14/163, D-dimer and IFN-gamma assays will be performed on the blood to identify levels of pro-inflammatory markers.

Time frame:
Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
Reported as:
Mean · pg/mL (picograms per milliliter)
Pro-Inflammatory Markers
pg/mL (picograms per milliliter)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Tumor Necrosis Factor - Alpha (TNF-alpha)2.00 ± 0.8011.996 ± 0.5491.689 ± 0.6561.563 ± 0.672
Interleukin-6 (IL-6)1.314 ± 1.0092.234 ± 2.3761.482 ± 0.9061.077 ± 0.811
Interleukin-12 (IL-12)0.212 ± 0.1220.279 ± 0.1370.269 ± 0.2190.412 ± 1.019
Interleukin - 8 (IL-8)9.603 ± 6.40710.919 ± 5.4205.949 ± 3.3287.115 ± 6.817
C-reactive protein (CRP)4953.320 ± 6362.0964759.150 ± 5071.1015245.094 ± 5503.5994233.468 ± 7156.568
sCD141.457 ± 0.3011.585 ± 0.3611.427 ± 0.2481.325 ± 0.235
D-Dimer294.602 ± 180.747288.472 ± 129.5481264.445 ± 3973.323611.577 ± 1358.858
IFN-gamma7.888 ± 10.3897.675 ± 5.2814.866 ± 4.3567.837 ± 14.118
PrimaryAnti-Inflammatory Markers

IFN-a, TGF-B, IL4, IL-10 and IL-13 assays will be performed on the blood to identify levels of anti-inflammatory markers.

Time frame:
Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
Reported as:
Mean · pg/mL (picograms per milliliter)
Anti-Inflammatory Markers
pg/mL (picograms per milliliter)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Interleukin-10 (IL-10)0.341 ± 0.3330.372 ± 0.2370.267 ± 0,1170.317 ± 0.303
Interleukin-13 (IL-13)0.608 ± 0.0560.703 ± 0.0251.058 ± 0.5061.016 ± 0.833
Transforming Growth Factor - Beta 1 (TGF-B1)119.192 ± 31.347104.864 ± 27.557133.785 ± 37.426137.187 ± 32.185
PrimaryOxidative Stress Markers

Mitochondrial DNA damage, Damage associated molecular patterns (DAMPS) and Cortisol assays will be performed on the blood to identify levels of oxidative stress markers.

Time frame:
Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
Reported as:
Mean · micrograms per deciliter (µg/dL)
Oxidative Stress Markers
micrograms per deciliter (µg/dL)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Cortisol9.644 ± 4.55611.237 ± 4.55910.246 ± 3.79610.829 ± 4.092
Mitochondrial DAMPS - ND12.260 ± 3.8111.815 ± 1.9861.335 ± 1.3111.889 ± 1.387
Mitochondrial DAMPS - ND62.303 ± 5.7401.269 ± 0.7251.090 ± 0.8571.311 ± 0.913
PrimaryPain Threshold

Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful"

Time frame:
pain threshold assessed at Week 2; data is average of three assessments
Reported as:
Mean · Degrees Celsius
Pain Threshold
Degrees CelsiusHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Pain Threshold43.39 ± 3.6042.18 ± 4.0144.12 ± 3.2143.15 ± 4.09
PrimaryPain Tolerance

Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation.

Time frame:
pain tolerance assessed at Week 2; data is average of three assessments
Reported as:
Mean · Degrees Celsius
Pain Tolerance
Degrees CelsiusHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Pain Tolerance47.26 ± 2.4246.51 ± 2.1847.28 ± 2.3147.19 ± 2.92
PrimaryPunctate Stimuli

Mechanical temporal summation was assessed using a nylon Von Frey Filament (Stoelting Co., 6.65 g), which is calibrated to bend at 300 g of pressure. The filament was applied to the back of the non-dominant hand for approximately 1 second until the monofilament bent slightly. Participants were instructed to rate their pain level using the 0-100 Numeric Rating Scale (higher numbers represent greater pain). The filament was then applied to the skin for a series of 10 consecutive applications. Participants were instructed to rate the highest level of pain they experienced during the trial. This process was repeated for two trials (2 single trials, 2 series of 10). For each trial, a difference score was calculated between the series of 10 applications and the single presentation, which represented mechanical TS. The difference score was averaged across the two trials.

Time frame:
mechanical temporal summation of pain assessed at Week 2; data is average of two test trials
Reported as:
Mean · Units on a scale
Punctate Stimuli
Units on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Punctate Stimuli20.60 ± 3.4726.28 ± 5.7014.53 ± 3.4715.43 ± 3.15
PrimaryTemporal Summation of Pain

Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. A series of 5 heat pulses will be repeated every two seconds starting at a baseline temperature of 40 and participants will be asked to rate how painful each peak of the pulse feels to them using a pain rating of 0-100 numeric rating scale. Pain intensity was assessed using a 0-100 numeric rating scale, where 0 indicates no pain and 100 indicates the worst pain imaginable. Participants rated their pain intensity, with higher scores indicating greater pain severity. Temperatures included 44, 46, and 48 degrees in Celsius.

Time frame:
heat temporal summation of pain assessed at Week 2; data presented is the average of 5 heat pulses completed at 44, 46, and 48 degrees in Celsius.
Reported as:
Mean · units on a scale
Temporal Summation of Pain
units on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Temporal summation at 44 degrees Celsius33.99 ± 28.8229.33 ± 22.5529.69 ± 22.3933.48 ± 23.86
Temporal summation at 46 degrees Celsius47.72 ± 32.7742.95 ± 29.0642.34 ± 27.0646.71 ± 27.59
Temporal summation at 48 degrees Celsius60.45 ± 31.2256.86 ± 27.2651.31 ± 31.5855.05 ± 28.67
PrimaryConditioned Pain Modulation

A cold-water bath (conditioning stimulus) was set to 10°C prior to the visit. Participants placed their non-dominant hand in the water bath up to their wrist for a maximum of 60 seconds. Immediately after withdrawal of the hand from the cold water, pressure was then applied to the dominant forearm or trapezius muscle using an algometer (testing stimulus). Participants were instructed to press a button when they first felt pain, resulting in termination of the stimuli. This procedure was repeated for a total of 4 trials (2 on each body site) and body site order was randomized (i.e., Forearm, Trapezius, Forearm, Trapezius, Forearm). An average pressure pain threshold score (kiloPascals - kPa of pressure) was generated across the two trials at each site after water immersion. Conditioned pain modulation was calculated as the difference score between baseline pressure pain threshold (kPa) and the average pressure pain threshold after water immersion at each body site

Time frame:
Week 2
Reported as:
Mean · kiloPascals of Pressure
Conditioned Pain Modulation
kiloPascals of PressureHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Conditioned pain modulation tested at the forearm-3.40 ± 17.1251.64 ± 28.095.54 ± 17.0913.41 ± 15.53
Conditioned pain modulation tested at the trapezius27.27 ± 15.9830.05 ± 26.2121.78 ± 15.9537.16 ± 14.49
PrimaryActigraph Sleep Measurement

A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light.

Time frame:
seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
Reported as:
Mean · Minutes
Actigraph Sleep Measurement
MinutesHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
actigraphic wake after sleep onset (WASO)63.20 ± 4.3562.98 ± 7.0751.51 ± 4.3942.28 ± 4.18
actigraphic sleep onset latency (SOL)40.59 ± 4.3917.17 ± 7.1429.89 ± 4.4323.46 ± 4.22
PrimaryWeekly Sleep Diaries

A sleep diary including daily questions will be filled out every day for seven days including questions about a participants nightly sleep experiences.

Time frame:
Baseline up to 8 weeks
Reported as:
Mean · Average minutes of nightly sleep
Weekly Sleep Diaries
Average minutes of nightly sleepHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Weekly Sleep Diaries372.285 ± 92.831441.551 ± 76.698401.730 ± 78.200441.286 ± 72.781
PrimaryWeekly Caffeine Diaries

A caffeine dairy including different types of caffeine generally available for the participants to record their daily caffeine consumption of for seven days.

Time frame:
Baseline up to 8 weeks
Reported as:
Mean · Average number of days per week
Weekly Caffeine Diaries
Average number of days per weekHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Weekly Caffeine Diaries4.900 ± 2.5115.917 ± 2.3143.680 ± 2.3575.022 ± 2.580
SecondaryShort Physical Performance Battery

The Short Physical Performance Battery consists of 3 individual sub-tests - standing balance (participants are asked to stand in 3 easy stances for 10 seconds), 4-meter gait speed (participants are asked to walk a steady pace in a straight line for 4-meters) and 5-repetition sit-to-stand (participants are asked to stand up and sit back down in a stable chair up to 5 times). All 3 are simple and quick to perform in the outpatient setting and require only limited equipment. The total short physical performance battery score ranges from 0-12, with higher scores indicating better physical performance.

Time frame:
Completed at Week 3 by people with insomnia only
Reported as:
Mean · Scores on a scale
Short Physical Performance Battery
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Short Physical Performance Battery9.29 ± 1.204—10.33 ± 1.238—
Other pre-specifiedTimed Up and Go (TUG) Task

The Timed Up and Go test (TUG) is a commonly used screening tool to assist clinicians to identify patients at risk of falling. Participants are asked to start in a sitting position in a chair, stand up and walk approximately 3 meters before turning to return to the chair at a steady, straight pace. The outcome will be measured with a stopwatch, then rating difficulty 0-100 (0 no difficulty and 100 being the most difficult imaginable) and pain 0-100 (0 no pain and 100 being the most pain imaginable).

Time frame:
Completed at Week 3 by people with insomnia only
Reported as:
Mean · Seconds
Timed Up and Go (TUG) Task
SecondsHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Timed Up and Go (TUG) Task10.787 ± 3.104—8.313 ± 2.514—
Other pre-specifiedMunich Chrono Type Questionnaires (MCTQ)

The Munich Chronotype Questionnaire (MCTQ) estimates chronotype primarily from the midpoint of sleep on free days, called MSF (mid-sleep on free days), with MSFsc (sleep-corrected MSF) generally preferred because it adjusts for accumulated weekday sleep debt. The outcome reported in this trial is expressed in minutes - "mid-sleep time on free days, sleep-corrected (minutes). Higher values represent a later/evening chronotype, whereas lower values represent an earlier/morning chronotype.

Time frame:
Baseline
Reported as:
Mean · Minutes
Munich Chrono Type Questionnaires (MCTQ)
MinutesHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Munich Chrono Type Questionnaires (MCTQ)314 ± 348288 ± 327263 ± 284237 ± 171
Other pre-specifiedInsomnia Severity Index (ISI)

The Insomnia severity index is a 7 item measure that has each participant subjectively measure their insomnia severity. Each is rated from 0 (none/not at all) to 4 (very severe/very much). The responses are summed to produce a total score that ranges from 0 to 28; higher scores suggest great subjective insomnia severity.

Time frame:
ISI completed Week 1
Reported as:
Mean · Scores on a scale
Insomnia Severity Index (ISI)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Insomnia Severity Index (ISI)24.076 ± 5.17715.095 ± 6.03222.279 ± 4.80710.907 ± 3.783
Other pre-specifiedDemographics (DEMO)

This questionnaire better helps the investigators understand how each participant's financial, racial, social, etc. background. It ranges from general questions such as age and birthday, to socioeconomic questions such as work status and financial stability.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Demographics (DEMO)
ParticipantsHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Education attainment; high school or greater36163850
Educational attainment; less than high school17554
Other pre-specifiedCenter for Epidemiological Studies - Depression (CESD)

The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report measure of depressive symptoms experienced during the past week, with each item scored 0-3 for a total of 0-60. Commonly used cutoffs are \<16 = no significant depressive symptomatology, 16-26 = mild/moderate symptoms, and ≥27 = severe symptoms, although the CES-D is a screening measure rather than a diagnostic instrument. Higher scores indicate greater depressive symptom burden.

Time frame:
CESD completed Week 1
Reported as:
Mean · Scores on a scale
Center for Epidemiological Studies - Depression (CESD)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Center for Epidemiological Studies - Depression (CESD)19.50 ± 10.89910.929 ± 8.34315.919 ± 9.9489.979 ± 8.104
Other pre-specifiedRU Sated

Sleep is a key aspect in an individual's everyday life. This questionnaire measures overall sleep quality in six different categories---Regularity, Sleep quality, alertness, timing, efficiency, and duration. This helps investigators understand a person's sleep efficacy.

Time frame:
RU Sated completed Week 1
Reported as:
Mean · Scores on a scale
RU Sated
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
RU Sated5.509 ± 2.4142.200 ± 2.8585.837 ± 2.1039.241 ± 2.109
Other pre-specifiedPhysical Health Questionnaire (PHQ-15)

The PHQ-15 (Patient Health Questionnaire-15) is a 15-item self-report measure of somatic symptom burden, with each symptom scored 0 (not bothered), 1 (bothered a little), or 2 (bothered a lot), producing a total score of 0-30. Commonly used severity categories are 0-4 = minimal, 5-9 = low, 10-14 = medium, and 15-30 = high somatic symptom severity.

Time frame:
Baseline
Reported as:
Mean · Scores on a scale
Physical Health Questionnaire (PHQ-15)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Physical Health Questionnaire (PHQ-15)10.094 ± 4.9705.571 ± 4.4229.023 ± 3.7123.352 ± 3.742
Other pre-specifiedDifficulties in Emotion Regulation Scale (DERS)

The Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report measure assessing difficulties with emotion regulation across six domains, with items typically rated 1 (almost never) to 5 (almost always), yielding a total score of 36-180. Higher scores indicate greater emotion-regulation difficulties, and there are no universally accepted clinical cutoff scores; scores are generally interpreted relative to normative samples or as continuous measures of emotion-regulation difficulty.

Time frame:
Baseline
Reported as:
Mean · Scores on a scale
Difficulties in Emotion Regulation Scale (DERS)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Difficulties in Emotion Regulation Scale (DERS)77.226 ± 21.80367.333 ± 23.96371.534 ± 21.22563.296 ± 13.941
Other pre-specifiedDysfunctional Beliefs and Attitudes About Sleep (DBAAS)

The Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) assesses maladaptive beliefs and expectations about sleep; the commonly used DBAS-16 contains 16 items rated on a 0-10 scale, producing a mean score from 0-10. Higher scores indicate stronger dysfunctional sleep beliefs.

Time frame:
Week 1
Reported as:
Mean · Scores on a scale
Dysfunctional Beliefs and Attitudes About Sleep (DBAAS)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Dysfunctional Beliefs and Attitudes About Sleep (DBAAS)5.992 ± 2.1803.857 ± 2.1034.635 ± 1.5772.901 ± 1.413
Other pre-specifiedPain Interference and Intensity (PI-I)

This questionnaire seeks to understand how pain has an influence/impacts an individual's everyday life and activities, sleep, and mood in general. Pain intensity and interference in everyday life was assessed using a 0-5 numeric rating scale, where 0 indicates no pain and 5 indicates the worst pain imaginable. Participants rated their pain intensity and interference, with higher scores indicating greater pain severity.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Pain Interference and Intensity (PI-I)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Pain Intensity2.829 ± 0.9452.500 ± 1.2112.171 ± 0.8181.527 ± 0.687
Pain Interference2.496 ± 1.0532.267 ± 1.1791.743 ± 0.8991.322 ± 0.742
Other pre-specifiedSorge 24 Hour Food Record

Dietary intake will be assessed using Sorge 24-hour Food Records. These records will be analyzed with the Nutrition Data System for Research (NDSR), a computer-based dietary assessment software developed by the Nutrition Coordinating Center at the University of Minnesota. Trained interviewers document all foods, beverages, and, when applicable, dietary supplements consumed during the preceding 24 hours. Information regarding food type, portion size, ingredients, preparation methods, and consumption occasions will be collected to improve the completeness and accuracy of dietary reporting. The reported dietary intake will be entered into NDSR and the resulting data may include total energy intake, macronutrients, micronutrients, and other dietary components. NDSR access is proprietary and requires a subscription. We did not have the funds to access NDSR and thus we do not have resulting data to present. The numbers below represent completed 24 hour food records for each group.

Time frame:
Food record completed once during Week 2
Reported as:
Count of participants · Participants
Sorge 24 Hour Food Record
ParticipantsHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Sorge 24 Hour Food Record53214354
Other pre-specifiedSorge Dietary Habits

This questionnaire asks about a person's general diet and intake.

Time frame:
Sorge dietary habits completed once at Week 2
Reported as:
Count of participants · Participants
Sorge Dietary Habits
ParticipantsHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Self-reported diet quality - "Excellent"1010
Self-reported diet quality - "Very good"92410
Self-reported diet quality - "Good"1071123
Self-reported diet quality - "Fair"1531612
Self-reported diet quality - "Poor"2252
Other pre-specifiedDrug Abuse Screening Test (DAST10)

The DAST-10 (Drug Abuse Screening Test-10) is a 10-item self-report screening measure of drug-related problems, with each yes/no item scored 0 or 1, producing a total score of 0-10. Common interpretation is 0 = no problems, 1-2 = low level, 3-5 = moderate, 6-8 = substantial, and 9-10 = severe drug-related problems; it is a screening tool rather than a diagnostic measure.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Drug Abuse Screening Test (DAST10)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Drug Abuse Screening Test (DAST10)6.421 ± 5.1556.571 ± 6.3452.081 ± 2.9092.234 ± 3.484
Other pre-specifiedState Trait Anxiety Inventory

The State-Trait Anxiety Inventory-Trait (STAI-T) is a 20-item self-report measure of relatively stable, enduring anxiety proneness, with each item rated 1-4, producing a total score of 20-80. Higher scores indicate greater trait anxiety, but there are no universally accepted clinical severity cutoffs; scores are generally interpreted relative to normative populations, with higher scores reflecting greater anxiety tendency.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
State Trait Anxiety Inventory
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
State Trait Anxiety Inventory51.567 ± 3.19053.286 ± 3.89151.297 ± 3.79251.979 ± 3.371
Other pre-specifiedPenn State Cigarette Dependence Index - Cigarettes

The Penn State Cigarette Dependence Index (PSCDI) is a brief self-report measure of cigarette dependence, assessing factors such as smoking frequency, time to first cigarette, and difficulty refraining from smoking. The commonly used 9-item version produces a score of 0-9, with higher scores indicating greater nicotine dependence; there are no universally accepted clinical severity cutoffs, so scores are typically interpreted continuously or using study-specific thresholds.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Penn State Cigarette Dependence Index - Cigarettes
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Penn State Cigarette Dependence Index - Cigarettes8.447 ± 6.4255.923 ± 5.5141.378 ± 3.5921.021 ± 3.007
Other pre-specifiedPenn State Cigarette Dependence Index - Ecigarettes

The Penn State Electronic Cigarette Dependence Index (Penn State ECigarette Dependence Index; PS-ECDI) is a brief self-report measure of e-cigarette/vaping dependence, assessing features such as frequency of use, time to first use, and difficulty refraining. The 10-item version is scored from 0-20, with higher scores indicating greater e-cigarette dependence; commonly used categories are 0-3 = no dependence, 4-8 = low, 9-12 = moderate, 13-16 = high, and 17-20 = very high dependence.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Penn State Cigarette Dependence Index - Ecigarettes
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Penn State Cigarette Dependence Index - Ecigarettes8.500 ± 3.8724.000 ± 1.41410.250 ± 0.9578.000 ± 0.000
Other pre-specifiedAlcohol Use Disorders Identification Test - C (AUDIT)

The AUDIT-C (Alcohol Use Disorders Identification Test-Consumption) is a 3-item screening measure of alcohol consumption, with each item scored 0-4, producing a total score of 0-12. Higher scores indicate greater alcohol consumption and likelihood of hazardous drinking.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Alcohol Use Disorders Identification Test - C (AUDIT)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Alcohol Use Disorders Identification Test - C (AUDIT)3.184 ± 2.6892.643 ± 2.6192.405 ± 2.2172.340 ± 2.139
Other pre-specifiedAlcohol Smoking and Substance Involvement Screening Test (ASSIST)

This questionnaire detects and measures substance abuse, alcohol, and smoking as well as related problems. It aims to detect the risky behavior related to each.

Time frame:
Baseline up to 1 week
Reported as:
Count of participants · Participants
Alcohol Smoking and Substance Involvement Screening Test (ASSIST)
ParticipantsHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Lifetime use of Tobacco Products: Count = % reporting "yes"29111917
Lifetime use of Tobacco Products: Count = % reporting "no"831830
Other pre-specifiedAnger PROMIS

The 22-item PROMIS Anger scale is a self-report measure of anger and irritability, with each item typically rated from 1 (never) to 5 (always), yielding a raw score of 22-110. Higher raw scores indicate greater anger, but raw scores are not usually interpreted with fixed clinical severity cutoffs.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Anger PROMIS
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Anger PROMIS49.816 ± 16.89645.143 ± 17.10541.649 ± 13.99238.167 ± 11.237
Other pre-specifiedPerceived Stress Scale (PSS)

The Perceived Stress Scale (PSS) is a 10-item self-report measure assessing how unpredictable, uncontrollable, and overwhelming respondents have found their lives during the past month. Each item is scored 0-4, producing a total raw score of 0-40; higher scores indicate greater perceived stress, but there are no universally accepted clinical severity cutoffs, so scores are generally interpreted continuously.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Perceived Stress Scale (PSS)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Perceived Stress Scale (PSS)20.289 ± 5.73718.214 ± 5.20617.919 ± 6.06215.354 ± 6.238
Other pre-specifiedPain Catastrophizing Scale (PCS)

The Pain Catastrophizing Scale (PCS) is a 13-item self-report measure assessing three aspects of pain catastrophizing: rumination, magnification, and helplessness. Each item is scored 0-4, producing a total raw score of 0-52; higher scores indicate greater pain catastrophizing, with ≥30 commonly used as a clinically relevant level of catastrophizing.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Pain Catastrophizing Scale (PCS)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Pain Catastrophizing Scale (PCS)17.868 ± 13.91512.786 ± 13.0168.162 ± 7.9986.208 ± 7.765
Other pre-specifiedHIV Stigma Mechanisms

the HIV Stigma Mechanisms Scale (HIV-SMS) assesses three distinct dimensions of HIV-related stigma: enacted (promulgated) stigma, internalized stigma, and anticipated stigma. The original 24-item instrument uses separate five-point response scales for each dimension. Scoring and interpretation * Enacted stigma (9 items): Participants report how frequently they have experienced stigmatizing treatment because of their HIV status, using a five-point scale from 1 (never) to 5 (very often). * Internalized stigma (6 items): Participants rate their agreement with statements reflecting negative feelings or beliefs about themselves because of their HIV status, using a five-point scale from 1 (strongly disagree) to 5 (strongly agree). * Anticipated stigma (9 items): Participants rate how likely they believe others are to treat them in stigmatizing ways because of their HIV status, using a five-point scale from 1 (very unlikely) to 5 (very likely).

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
HIV Stigma Mechanisms
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Internalized HIV Stigma2.626 ± 1.4582.271 ± 0.972——
Anticipated HIV Stigma3.495 ± 1.6522.924 ± 1.236——
Enacted HIV Stigma2.757 ± 1.3322.743 ± 1.287——
Other pre-specifiedHeightened Vigilance Scale (HVS)

The Heightened Vigilance Scale is a 6-item self-report measure assessing the extent to which individuals feel they must remain alert and cautious because of the possibility of experiencing unfair treatment or discrimination. Each item is typically rated on a 1-6 scale, producing a total score of 6-36, with higher scores indicating greater perceived vigilance.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Heightened Vigilance Scale (HVS)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Heightened Vigilance Scale (HVS)14.132 ± 6.20011.857 ± 6.65412.108 ± 5.02111.583 ± 4.823
Other pre-specifiedExperience of Discrimination (EOD)

The 9-item Experiences of Discrimination (EOD) measure assesses lifetime experiences of discrimination across nine settings, including school, employment, housing, health care, and public settings. Each item is scored according to whether the participant reports experiencing discrimination in that setting. For a situation-based total score, responses are coded as 0 (no) or 1 (yes) and summed across the nine items, yielding a total score ranging from 0 to 9. Higher scores indicate experiences of discrimination across a greater number of settings and therefore represent a worse outcome.

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Experience of Discrimination (EOD)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Experience of Discrimination (EOD)2.632 ± 3.0793.143 ± 2.3812.676 ± 2.6561.553 ± 2.009
Other pre-specifiedAdverse Childhood Experiences (ACE)

The Adverse Childhood Experiences (ACE) Questionnaire is a 10-item retrospective self-report measure assessing exposure to potentially traumatic or stressful experiences before age 18, including abuse, neglect, and household dysfunction. Each experience is typically scored 0 (no) or 1 (yes), producing a total ACE score of 0-10, with higher scores indicating exposure to a greater number of adverse childhood experiences

Time frame:
Week 2
Reported as:
Mean · Scores on a scale
Adverse Childhood Experiences (ACE)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Adverse Childhood Experiences (ACE)4.081 ± 2.6713.357 ± 2.4992.378 ± 2.1901.787 ± 1.966
Other pre-specifiedLee Fatigue Scale (LFS)

The Lee Fatigue Scale (LFS) is an 18-item self-report measure assessing fatigue severity and energy level, with items rated on a 0-10 scale. Scores are typically averaged across items to produce a 0-10 overall fatigue score, with higher scores indicating greater fatigue

Time frame:
Week 3
Reported as:
Mean · Scores on a scale
Lee Fatigue Scale (LFS)
Scores on a scaleHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Lee Fatigue Scale (LFS)4.956 ± 1.869—4.630 ± 1.215—
PrimaryActigraph Sleep Measurement

A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light. The primary actigraphic sleep outcome presented here is sleep efficiency. Sleep efficiency will be assessed using wrist-worn actigraphy and calculated as the percentage of time spent asleep relative to the total time spent in bed during the designated sleep period. Sleep efficiency is derived by dividing total sleep time by time in bed and multiplying by 100. The mean scores presented here are percentages. Higher percentages indicate greater sleep efficiency.

Time frame:
seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
Reported as:
Mean · Percentage
Actigraph Sleep Measurement
PercentageHIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-
Actigraph Sleep Measurement74.25 ± 1.8281.32 ± 2.9778.40 ± 1.8479.97 ± 1.75

Adverse events

Collected over From enrollment until end of the follow-up, to to 3 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HIV+/Insomnia+0/53 (0%)0/53 (0%)0/53 (0%)
HIV+/Insomnia-0/21 (0%)0/21 (0%)0/21 (0%)
HIV-/Insomnia+0/43 (0%)0/43 (0%)0/43 (0%)
HIV-/Insomnia-0/54 (0%)0/54 (0%)0/54 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-Total
Mean49.94 ± 10.15752.62 ± 12.16441.95 ± 13.2441.02 ± 12.92146.38 ± 12.121
Sex: Female, Male
Sex: Female, Male(Participants)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-Total
Female254303291
Male2817132280
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-Total
American Indian or Alaska Native00011
Asian00314
Native Hawaiian or Other Pacific Islander00000
Black or African American48172430119
White43162043
More than one race10023
Unknown or Not Reported01001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-Total
Hispanic or Latino11046
Not Hispanic or Latino52204349164
Unknown or Not Reported00011
Chronic Pain Status
Chronic Pain Status(Participants)HIV+/Insomnia+HIV+/Insomnia-HIV-/Insomnia+HIV-/Insomnia-Total
Count of participants32921870
08

Study locations

1 site
  • UAB
    Birmingham, Alabama 35294, United States
09

References and documents

Publications

  • Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, Lederman MM, Landay AL. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15;210(8):1248-59. doi: 10.1093/infdis/jiu254. Epub 2014 May 1. PubMed 24795473 ↗
  • Goodin BR, Owens MA, Yessick LR, Rainey RL, Okunbor JI, White DM, Mushatt KA, Harmon OA, Heath SL, Merlin JS. Detectable Viral Load May Be Associated with Increased Pain Sensitivity in Persons Living with HIV: Preliminary Findings. Pain Med. 2017 Dec 1;18(12):2289-2295. doi: 10.1093/pm/pnx057. PubMed 28398572 ↗
  • Merlin JS, Westfall AO, Heath SL, Goodin BR, Stewart JC, Sorge RE, Younger J. Brief Report: IL-1beta Levels Are Associated With Chronic Multisite Pain in People Living With HIV. J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):e99-e103. doi: 10.1097/QAI.0000000000001377. PubMed 28328552 ↗
  • Webb CK, Gilstrap Wilson SR, Hobson JM, Stallworth HN, White-Gilliam DM, Owens MA, Cody SL, Justin Thomas S, Sorge RE, Goodin BR. Living with HIV and Insomnia: Implications for sleep quality, experimental pain sensitivity, and clinical pain severity. J Pain. 2026 Jul;44:106283. doi: 10.1016/j.jpain.2026.106283. Epub 2026 Apr 15. PubMed 41997468 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jul 2025, 66 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 127 non-industry observational studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's 66 months is above that.

Counting every sponsor, half of 138 studies reached it within 18 months; a quarter within 4 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Mar 6, 2020
StartActual
Jan 1, 2020
Primary completionActual
Jul 31, 2025
CompletionActual
Jul 31, 2025
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Primary outcomes
7 edited, 2 time frame changed, 1 added, 2 description edited
What changed in the outcomes
  • EditedPro-Inflammatory markersMarkersTime frame: Baseline up to 8 weeks → Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
  • EditedAnti-Inflammatory markersMarkersTime frame: Baseline up to 8 weeks → Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
  • EditedOxidative Stress markersMarkersTime frame: Baseline up to 8 weeks → Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
  • EditedPain thresholdThresholdTime frame: Baseline up to 1 week → pain threshold assessed at Week 2; data is average of three assessments
  • EditedPain toleranceToleranceTime frame: Baseline up to 1 week → pain tolerance assessed at Week 2; data is average of three assessments
  • EditedTemporal summationSummation of painPainTime frame: Baseline up to 1 week → heat temporal summation of pain assessed at Week 2; data presented is the average of 5 heat pulses completed at 44, 46, and 48 degrees in Celsius.
  • EditedConditioned pain modulationPain ModulationTime frame: Baseline up to 1 week → Week 2
  • AddedActigraph Sleep MeasurementTime frame: seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
  • Time framePunctate StimuliBaseline up to 1 week → mechanical temporal summation of pain assessed at Week 2; data is average of two test trials
  • Time frameActigraph Sleep MeasurementBaseline up to 8 weeks → seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
  • DescriptionPunctate Stimuli: how it is measured was reworded
  • DescriptionWeekly Sleep Diaries: how it is measured was reworded
Nov 12, 2026
Documents
Secondary outcomes
1 edited, 21 time frame changed, 8 description edited, 13 more
What changed in the outcomes
  • Time frameShort Physical Performance BatteryWeek 2 up to 8 weeks → Completed at Week 3 by people with insomnia only
  • DescriptionShort Physical Performance Battery: how it is measured was reworded
  • Editedother outcomeDysfunctional Beliefs and Attitudes aboutAbout Sleep (DBAAS)Time frame: Baseline → Week 1
  • Time frameother outcomeTimed Up and Go (TUG) TaskWeek 2 up to 8 weeks → Completed at Week 3 by people with insomnia only
  • Time frameother outcomeInsomnia Severity Index (ISI)Baseline up to 8 weeks → ISI completed Week 1
  • Time frameother outcomeCenter for Epidemiological Studies - Depression (CESD)Baseline up to 8 weeks → CESD completed Week 1
  • Time frameother outcomeRU SatedBaseline up to 8 weeks → RU Sated completed Week 1
  • Time frameother outcomePain Interference and Intensity (PI-I)week 1 up to 7 weeks → Week 2
  • Time frameother outcomeSorge 24 Hour Food RecordBaseline up to 1 week → Food record completed once during Week 2
  • Time frameother outcomeSorge Dietary HabitsBaseline up to 1 week → Sorge dietary habits completed once at Week 2
  • Time frameother outcomeDrug Abuse Screening Test (DAST10)Baseline up to 1 week → Week 2
  • Time frameother outcomeState Trait Anxiety InventoryBaseline up to 1 week → Week 2
  • Time frameother outcomePenn State Cigarette Dependence Index - CigarettesBaseline up to 1 week → Week 2
  • Time frameother outcomePenn State Cigarette Dependence Index - EcigarettesBaseline up to 1 week → Week 2
  • Time frameother outcomeAlcohol Use Disorders Identification Test - C (AUDIT)Baseline up to 1 week → Week 2
  • Time frameother outcomeAnger PROMISBaseline up to 1 week → Week 2
  • Time frameother outcomePerceived Stress Scale (PSS)Baseline up to 1 week → Week 2
  • Time frameother outcomePain Catastrophizing Scale (PCS)Baseline up to 1 week → Week 2
  • Time frameother outcomeHIV Stigma MechanismsBaseline up to 1 week → Week 2
  • Time frameother outcomeHeightened Vigilance Scale (HVS)Baseline up to 1 week → Week 2
  • Time frameother outcomeExperience of Discrimination (EOD)Baseline up to 1 week → Week 2
  • Time frameother outcomeAdverse Childhood Experiences (ACE)Baseline up to 1 week → Week 2
  • Time frameother outcomeLee Fatigue Scale (LFS)Baseline up to 1 week → Week 3
  • Descriptionother outcomeAdverse Childhood Experiences (ACE): how it is measured was reworded
  • Descriptionother outcomeAlcohol Use Disorders Identification Test - C (AUDIT): how it is measured was reworded
  • Descriptionother outcomeAnger PROMIS: how it is measured was reworded
  • Descriptionother outcomeCenter for Epidemiological Studies - Depression (CESD): how it is measured was reworded
  • Descriptionother outcomeDifficulties in Emotion Regulation Scale (DERS): how it is measured was reworded
  • Descriptionother outcomeDrug Abuse Screening Test (DAST10): how it is measured was reworded
  • Descriptionother outcomeExperience of Discrimination (EOD): how it is measured was reworded
  • …and 13 more, on the record history on ClinicalTrials.gov ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Primary outcomes 7 edited, 2 time frame changed, 1 added, 2 description edited
    What changed in the outcomes
    • EditedPro-Inflammatory markersMarkersTime frame: Baseline up to 8 weeks → Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
    • EditedAnti-Inflammatory markersMarkersTime frame: Baseline up to 8 weeks → Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
    • EditedOxidative Stress markersMarkersTime frame: Baseline up to 8 weeks → Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
    • EditedPain thresholdThresholdTime frame: Baseline up to 1 week → pain threshold assessed at Week 2; data is average of three assessments
    • EditedPain toleranceToleranceTime frame: Baseline up to 1 week → pain tolerance assessed at Week 2; data is average of three assessments
    • EditedTemporal summationSummation of painPainTime frame: Baseline up to 1 week → heat temporal summation of pain assessed at Week 2; data presented is the average of 5 heat pulses completed at 44, 46, and 48 degrees in Celsius.
    • EditedConditioned pain modulationPain ModulationTime frame: Baseline up to 1 week → Week 2
    • AddedActigraph Sleep MeasurementTime frame: seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
    • Time framePunctate StimuliBaseline up to 1 week → mechanical temporal summation of pain assessed at Week 2; data is average of two test trials
    • Time frameActigraph Sleep MeasurementBaseline up to 8 weeks → seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
    • DescriptionPunctate Stimuli: how it is measured was reworded
    • DescriptionWeekly Sleep Diaries: how it is measured was reworded
    Secondary outcomes 1 edited, 21 time frame changed, 8 description edited, 13 more
    What changed in the outcomes
    • Time frameShort Physical Performance BatteryWeek 2 up to 8 weeks → Completed at Week 3 by people with insomnia only
    • DescriptionShort Physical Performance Battery: how it is measured was reworded
    • Editedother outcomeDysfunctional Beliefs and Attitudes aboutAbout Sleep (DBAAS)Time frame: Baseline → Week 1
    • Time frameother outcomeTimed Up and Go (TUG) TaskWeek 2 up to 8 weeks → Completed at Week 3 by people with insomnia only
    • Time frameother outcomeInsomnia Severity Index (ISI)Baseline up to 8 weeks → ISI completed Week 1
    • Time frameother outcomeCenter for Epidemiological Studies - Depression (CESD)Baseline up to 8 weeks → CESD completed Week 1
    • Time frameother outcomeRU SatedBaseline up to 8 weeks → RU Sated completed Week 1
    • Time frameother outcomePain Interference and Intensity (PI-I)week 1 up to 7 weeks → Week 2
    • Time frameother outcomeSorge 24 Hour Food RecordBaseline up to 1 week → Food record completed once during Week 2
    • Time frameother outcomeSorge Dietary HabitsBaseline up to 1 week → Sorge dietary habits completed once at Week 2
    • Time frameother outcomeDrug Abuse Screening Test (DAST10)Baseline up to 1 week → Week 2
    • Time frameother outcomeState Trait Anxiety InventoryBaseline up to 1 week → Week 2
    • Time frameother outcomePenn State Cigarette Dependence Index - CigarettesBaseline up to 1 week → Week 2
    • Time frameother outcomePenn State Cigarette Dependence Index - EcigarettesBaseline up to 1 week → Week 2
    • Time frameother outcomeAlcohol Use Disorders Identification Test - C (AUDIT)Baseline up to 1 week → Week 2
    • Time frameother outcomeAnger PROMISBaseline up to 1 week → Week 2
    • Time frameother outcomePerceived Stress Scale (PSS)Baseline up to 1 week → Week 2
    • Time frameother outcomePain Catastrophizing Scale (PCS)Baseline up to 1 week → Week 2
    • Time frameother outcomeHIV Stigma MechanismsBaseline up to 1 week → Week 2
    • Time frameother outcomeHeightened Vigilance Scale (HVS)Baseline up to 1 week → Week 2
    • Time frameother outcomeExperience of Discrimination (EOD)Baseline up to 1 week → Week 2
    • Time frameother outcomeAdverse Childhood Experiences (ACE)Baseline up to 1 week → Week 2
    • Time frameother outcomeLee Fatigue Scale (LFS)Baseline up to 1 week → Week 3
    • Descriptionother outcomeAdverse Childhood Experiences (ACE): how it is measured was reworded
    • Descriptionother outcomeAlcohol Use Disorders Identification Test - C (AUDIT): how it is measured was reworded
    • Descriptionother outcomeAnger PROMIS: how it is measured was reworded
    • Descriptionother outcomeCenter for Epidemiological Studies - Depression (CESD): how it is measured was reworded
    • Descriptionother outcomeDifficulties in Emotion Regulation Scale (DERS): how it is measured was reworded
    • Descriptionother outcomeDrug Abuse Screening Test (DAST10): how it is measured was reworded
    • Descriptionother outcomeExperience of Discrimination (EOD): how it is measured was reworded
    • …and 13 more, on the record history on ClinicalTrials.gov ↗
    + 5 other changes: identifiers, verification date, oversight details, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04298658
Responsible party
Burel Goodin (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Mar 6, 2020
Start date
Jan 1, 2020
Primary completion
Jul 31, 2025
Completion
Jul 31, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Burel R Goodin, PHd
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion